Process Systems Enterprise (PSE), the Advanced Process Modelling
company, today released version 1.4 of gPROMS FormulatedProducts, the
mechanistic model-based environment for integrated digital design of
robust formulated products and their manufacturing processes, and
related digital process operation.
This release introduces major enhancements to both the gPROMS
FormulatedProducts model libraries and the underlying gPROMS platform
6.0, including morphological crystallizer and sensor models to capture
particle size and shape evolution, enhanced continuous direct
compression models and improved wet granulation models. Platform
enhancements include support for cluster computing, to significantly
speed up execution of parameter estimation and other complex numerical
solutions, and comprehensive global system analysis of dynamic systems
for rapid exploration of the time-varying decision space and systematic
risk and uncertainty analysis.
Version 1.4 also introduces two key usability enhancements: the ability
to launch gPROMS FormulatedProducts Utilities from within the
flowsheeting environment to quickly and easily configure material
systems, and a user interface for rapid configuration of gPROMS
FormulatedProducts models for use in Perceptive Engineering’s PharmaMV
for digital operation applications.
Many of the platform and library enhancements in the new release were
enabled through the financial support of and collaborative activities
within the PSE-led ADDoPT project (www.addopt.org).
These enhancements were showcased on 28 March at the ADDoPT Digital
Design event, which included presentations from AstraZeneca, GSK, and
Pfizer on the application of mechanistic models for digital design and
operation of formulation and manufacturing processes.
Sean Bermingham, VP Formulated Products at PSE, said: “This release
constitutes a major improvement in terms of both capability and
usability for mechanistic model-based digital design and digital
operation, which will enable users across the formulated product
industries to design more robust products and processes, increase R&D
efficiency and reduce risk in innovation and technology transfer.”
PSE continues to lead innovation in advanced process modelling
capabilities for the pharmaceuticals, food & dairy, consumer products
and specialty chemicals sectors. Through the support of the ADDoPT
project and the Systems-based Pharmaceutics Alliance, by leveraging its
experience in the energy and chemicals sectors, and via support of
academic research and collaborative R&D initiatives, the company has
created first-in-pharma mechanistic modelling tools, methodologies and
workflows for both digital design and digital manufacturing.
For editors
‘About’: www.psenterprise.com/news/pr190418
View source version on businesswire.com: https://www.businesswire.com/news/home/20190419005026/en/